img

Global and United States CNS Oral Drugs Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States CNS Oral Drugs Market Report & Forecast 2024-2034

Market Analysis and InsightsGlobal and United States CNS Oral Drugs Market
This report focuses on global and United States CNS Oral Drugs market, also covers the segmentation data of other regions in regional level and county level.
The global CNS Oral Drugs revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In United States the CNS Oral Drugs revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of CNS Oral Drugs include Pfizer, Biogen, Otsuka, Novartis, Teva Pharmaceutical, Johnson & Johnson, AstraZeneca, Merck and GSK, etc. The global five biggest players hold a share of % in 2024.
Global CNS Oral Drugs Scope and Market Size
CNS Oral Drugs market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global CNS Oral Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the CNS Oral Drugs market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.



By Company


Pfizer
Biogen
Otsuka
Novartis
Teva Pharmaceutical
Johnson & Johnson
AstraZeneca
Merck
GSK
Eli Lilly and Company
Lundbeck
Takeda
Bristol Myers Squibb
Jiangsu Nhwa Pharmaceutical
Luye Pharma
Zhejiang Huahai Pharmaceutical
Chengdu Easton Biopharmaceuticals
Hansoh Pharmaceutical
Segment by Type
Antidepressants
Antipsychotics
Anti-Dementia Drugs
Anti-Parkinson's Drugs
Antiepileptic Drugs
Others

Segment by Application


Hospital and Clinic
Pharmacy
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces CNS Oral Drugs definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of CNS Oral Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of CNS Oral Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CNS Oral Drugs sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 CNS Oral Drugs Product Introduction
1.2 Global CNS Oral Drugs Outlook 2018 VS 2024 VS 2034
1.2.1 Global CNS Oral Drugs Sales in US$ Million for the Year 2018-2034
1.2.2 Global CNS Oral Drugs Sales in Volume for the Year 2018-2034
1.3 United States CNS Oral Drugs Outlook 2018 VS 2024 VS 2034
1.3.1 United States CNS Oral Drugs Sales in US$ Million for the Year 2018-2034
1.3.2 United States CNS Oral Drugs Sales in Volume for the Year 2018-2034
1.4 CNS Oral Drugs Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.4.1 The Market Share of United States CNS Oral Drugs in Global, 2018 VS 2024 VS 2034
1.4.2 The Growth Rate of CNS Oral Drugs Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.5 CNS Oral Drugs Market Dynamics
1.5.1 CNS Oral Drugs Industry Trends
1.5.2 CNS Oral Drugs Market Drivers
1.5.3 CNS Oral Drugs Market Challenges
1.5.4 CNS Oral Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 CNS Oral Drugs by Type
2.1 CNS Oral Drugs Market Segment by Type
2.1.1 Antidepressants
2.1.2 Antipsychotics
2.1.3 Anti-Dementia Drugs
2.1.4 Anti-Parkinson's Drugs
2.1.5 Antiepileptic Drugs
2.1.6 Others
2.2 Global CNS Oral Drugs Market Size by Type
2.2.1 Global CNS Oral Drugs Sales in Value, by Type (2018, 2024 & 2034)
2.2.2 Global CNS Oral Drugs Sales in Volume, by Type (2018, 2024 & 2034)
2.2.3 Global CNS Oral Drugs Average Selling Price (ASP) by Type (2018, 2024 & 2034)
2.3 United States CNS Oral Drugs Market Size by Type
2.3.1 United States CNS Oral Drugs Sales in Value, by Type (2018, 2024 & 2034)
2.3.2 United States CNS Oral Drugs Sales in Volume, by Type (2018, 2024 & 2034)
2.3.3 United States CNS Oral Drugs Average Selling Price (ASP) by Type (2018, 2024 & 2034)
3 CNS Oral Drugs by Application
3.1 CNS Oral Drugs Market Segment by Application
3.1.1 Hospital and Clinic
3.1.2 Pharmacy
3.2 Global CNS Oral Drugs Market Size by Application
3.2.1 Global CNS Oral Drugs Sales in Value, by Application (2018, 2024 & 2034)
3.2.2 Global CNS Oral Drugs Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 Global CNS Oral Drugs Average Selling Price (ASP) by Application (2018, 2024 & 2034)
3.3 United States CNS Oral Drugs Market Size by Application
3.3.1 United States CNS Oral Drugs Sales in Value, by Application (2018, 2024 & 2034)
3.3.2 United States CNS Oral Drugs Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 United States CNS Oral Drugs Average Selling Price (ASP) by Application (2018, 2024 & 2034)
4 Global CNS Oral Drugs Competitor Landscape by Company
4.1 Global CNS Oral Drugs Market Size by Company
4.1.1 Global Key Manufacturers of CNS Oral Drugs, Ranked by Revenue (2024)
4.1.2 Global CNS Oral Drugs Revenue by Manufacturer (2018-2023)
4.1.3 Global CNS Oral Drugs Sales by Manufacturer (2018-2023)
4.1.4 Global CNS Oral Drugs Price by Manufacturer (2018-2023)
4.2 Global CNS Oral Drugs Concentration Ratio (CR)
4.2.1 CNS Oral Drugs Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of CNS Oral Drugs in 2024
4.2.3 Global CNS Oral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of CNS Oral Drugs, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of CNS Oral Drugs, Product Offered and Application
4.5 Global Key Manufacturers of CNS Oral Drugs, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 United States CNS Oral Drugs Market Size by Company
4.7.1 Key Players of CNS Oral Drugs in United States, Ranked by Revenue (2024)
4.7.2 United States CNS Oral Drugs Revenue by Players (2018-2023)
4.7.3 United States CNS Oral Drugs Sales by Players (2018-2023)
5 Global CNS Oral Drugs Market Size by Region
5.1 Global CNS Oral Drugs Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global CNS Oral Drugs Market Size in Volume by Region (2018-2034)
5.2.1 Global CNS Oral Drugs Sales in Volume by Region: 2018-2023
5.2.2 Global CNS Oral Drugs Sales in Volume Forecast by Region (2024-2034)
5.3 Global CNS Oral Drugs Market Size in Value by Region (2018-2034)
5.3.1 Global CNS Oral Drugs Sales in Value by Region: 2018-2023
5.3.2 Global CNS Oral Drugs Sales in Value by Region: 2024-2034
6 Americas
6.1 Americas CNS Oral Drugs Market Size YoY Growth 2018-2034
6.2 Americas CNS Oral Drugs Sales in Volume, by Type (2018, 2024 & 2034)
6.3 Americas CNS Oral Drugs Sales in Volume, by Application (2018, 2024 & 2034)
6.4 Americas CNS Oral Drugs Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 Americas CNS Oral Drugs Sales in Value by Country (2018, 2024 & 2034)
6.4.2 Americas CNS Oral Drugs Sales in Volume by Country (2018, 2024 & 2034)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA CNS Oral Drugs Market Size YoY Growth 2018-2034
7.2 EMEA CNS Oral Drugs Sales in Volume, by Type (2018, 2024 & 2034)
7.3 EMEA CNS Oral Drugs Sales in Volume, by Application (2018, 2024 & 2034)
7.4 EMEA CNS Oral Drugs Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 EMEA CNS Oral Drugs Sales in Value by Country (2018, 2024 & 2034)
7.4.2 EMEA CNS Oral Drugs Sales in Volume by Country (2018, 2024 & 2034)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China CNS Oral Drugs Market Size YoY Growth 2018-2034
8.2 China CNS Oral Drugs Sales in Volume, by Type (2018, 2024 & 2034)
8.3 China CNS Oral Drugs Sales in Volume, by Application (2018, 2024 & 2034)
9 APAC
9.1 APAC CNS Oral Drugs Market Size YoY Growth 2018-2034
9.2 APAC CNS Oral Drugs Sales in Volume, by Type (2018, 2024 & 2034)
9.3 APAC CNS Oral Drugs Sales in Volume, by Application (2018, 2024 & 2034)
9.4 APAC CNS Oral Drugs Market Facts & Figures by Region (2018, 2024 & 2034)
9.4.1 APAC CNS Oral Drugs Sales in Value by Region (2018, 2024 & 2034)
9.4.2 APAC CNS Oral Drugs Sales in Volume by Region (2018, 2024 & 2034)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Description and Business Overview
10.1.3 Pfizer CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer CNS Oral Drugs Products Offered
10.1.5 Pfizer Recent Development
10.2 Biogen
10.2.1 Biogen Company Information
10.2.2 Biogen Description and Business Overview
10.2.3 Biogen CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Biogen CNS Oral Drugs Products Offered
10.2.5 Biogen Recent Development
10.3 Otsuka
10.3.1 Otsuka Company Information
10.3.2 Otsuka Description and Business Overview
10.3.3 Otsuka CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Otsuka CNS Oral Drugs Products Offered
10.3.5 Otsuka Recent Development
10.4 Novartis
10.4.1 Novartis Company Information
10.4.2 Novartis Description and Business Overview
10.4.3 Novartis CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Novartis CNS Oral Drugs Products Offered
10.4.5 Novartis Recent Development
10.5 Teva Pharmaceutical
10.5.1 Teva Pharmaceutical Company Information
10.5.2 Teva Pharmaceutical Description and Business Overview
10.5.3 Teva Pharmaceutical CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Teva Pharmaceutical CNS Oral Drugs Products Offered
10.5.5 Teva Pharmaceutical Recent Development
10.6 Johnson & Johnson
10.6.1 Johnson & Johnson Company Information
10.6.2 Johnson & Johnson Description and Business Overview
10.6.3 Johnson & Johnson CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Johnson & Johnson CNS Oral Drugs Products Offered
10.6.5 Johnson & Johnson Recent Development
10.7 AstraZeneca
10.7.1 AstraZeneca Company Information
10.7.2 AstraZeneca Description and Business Overview
10.7.3 AstraZeneca CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 AstraZeneca CNS Oral Drugs Products Offered
10.7.5 AstraZeneca Recent Development
10.8 Merck
10.8.1 Merck Company Information
10.8.2 Merck Description and Business Overview
10.8.3 Merck CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Merck CNS Oral Drugs Products Offered
10.8.5 Merck Recent Development
10.9 GSK
10.9.1 GSK Company Information
10.9.2 GSK Description and Business Overview
10.9.3 GSK CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 GSK CNS Oral Drugs Products Offered
10.9.5 GSK Recent Development
10.10 Eli Lilly and Company
10.10.1 Eli Lilly and Company Company Information
10.10.2 Eli Lilly and Company Description and Business Overview
10.10.3 Eli Lilly and Company CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Eli Lilly and Company CNS Oral Drugs Products Offered
10.10.5 Eli Lilly and Company Recent Development
10.11 Lundbeck
10.11.1 Lundbeck Company Information
10.11.2 Lundbeck Description and Business Overview
10.11.3 Lundbeck CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Lundbeck CNS Oral Drugs Products Offered
10.11.5 Lundbeck Recent Development
10.12 Takeda
10.12.1 Takeda Company Information
10.12.2 Takeda Description and Business Overview
10.12.3 Takeda CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Takeda CNS Oral Drugs Products Offered
10.12.5 Takeda Recent Development
10.13 Bristol Myers Squibb
10.13.1 Bristol Myers Squibb Company Information
10.13.2 Bristol Myers Squibb Description and Business Overview
10.13.3 Bristol Myers Squibb CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Bristol Myers Squibb CNS Oral Drugs Products Offered
10.13.5 Bristol Myers Squibb Recent Development
10.14 Jiangsu Nhwa Pharmaceutical
10.14.1 Jiangsu Nhwa Pharmaceutical Company Information
10.14.2 Jiangsu Nhwa Pharmaceutical Description and Business Overview
10.14.3 Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Products Offered
10.14.5 Jiangsu Nhwa Pharmaceutical Recent Development
10.15 Luye Pharma
10.15.1 Luye Pharma Company Information
10.15.2 Luye Pharma Description and Business Overview
10.15.3 Luye Pharma CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Luye Pharma CNS Oral Drugs Products Offered
10.15.5 Luye Pharma Recent Development
10.16 Zhejiang Huahai Pharmaceutical
10.16.1 Zhejiang Huahai Pharmaceutical Company Information
10.16.2 Zhejiang Huahai Pharmaceutical Description and Business Overview
10.16.3 Zhejiang Huahai Pharmaceutical CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Zhejiang Huahai Pharmaceutical CNS Oral Drugs Products Offered
10.16.5 Zhejiang Huahai Pharmaceutical Recent Development
10.17 Chengdu Easton Biopharmaceuticals
10.17.1 Chengdu Easton Biopharmaceuticals Company Information
10.17.2 Chengdu Easton Biopharmaceuticals Description and Business Overview
10.17.3 Chengdu Easton Biopharmaceuticals CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.17.4 Chengdu Easton Biopharmaceuticals CNS Oral Drugs Products Offered
10.17.5 Chengdu Easton Biopharmaceuticals Recent Development
10.18 Hansoh Pharmaceutical
10.18.1 Hansoh Pharmaceutical Company Information
10.18.2 Hansoh Pharmaceutical Description and Business Overview
10.18.3 Hansoh Pharmaceutical CNS Oral Drugs Sales, Revenue and Gross Margin (2018-2023)
10.18.4 Hansoh Pharmaceutical CNS Oral Drugs Products Offered
10.18.5 Hansoh Pharmaceutical Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 CNS Oral Drugs Industry Chain Analysis
11.2 CNS Oral Drugs Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 CNS Oral Drugs Production Mode & Process
11.4 CNS Oral Drugs Sales and Marketing
11.4.1 CNS Oral Drugs Sales Channels
11.4.2 CNS Oral Drugs Distributors
11.5 CNS Oral Drugs Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. CNS Oral Drugs CAGR in Value, United States VS Global, 2018 VS 2024 VS 2034
Table 2. CNS Oral Drugs Market Trends
Table 3. CNS Oral Drugs Market Drivers
Table 4. CNS Oral Drugs Market Challenges
Table 5. CNS Oral Drugs Market Restraints
Table 6. Global CNS Oral Drugs Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. United States CNS Oral Drugs Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global CNS Oral Drugs Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. United States CNS Oral Drugs Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Manufacturers of CNS Oral Drugs, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global CNS Oral Drugs Revenue by Manufacturer, (US$ Million), 2018-2023
Table 12. Global CNS Oral Drugs Revenue Share by Manufacturer, 2018-2023
Table 13. Global CNS Oral Drugs Sales by Manufacturer, (K Units), 2018-2023
Table 14. Global CNS Oral Drugs Sales Share by Manufacturer, 2018-2023
Table 15. Global CNS Oral Drugs Price by Manufacturer (2018-2023) & (US$/Unit)
Table 16. Global CNS Oral Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global CNS Oral Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CNS Oral Drugs as of 2024)
Table 18. Global Key Manufacturers of CNS Oral Drugs, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of CNS Oral Drugs, Product Offered and Application
Table 20. Global Key Manufacturers of CNS Oral Drugs, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of CNS Oral Drugs in United States, Ranked by Revenue (2024) & (US$ million)
Table 23. United States CNS Oral Drugs Revenue by Players, (US$ Million), (2018-2023)
Table 24. United States CNS Oral Drugs Revenue Share by Players, (2018-2023)
Table 25. United States CNS Oral Drugs Sales by Players, (K Units), (2018-2023)
Table 26. United States CNS Oral Drugs Sales Share by Players, (2018-2023)
Table 27. Global CNS Oral Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 28. Global CNS Oral Drugs Sales in Volume by Region (2018-2023) & (K Units)
Table 29. Global CNS Oral Drugs Sales in Volume Forecast by Region (2024-2034) & (K Units)
Table 30. Global CNS Oral Drugs Sales in Value by Region (2018-2023) & (US$ Million)
Table 31. Global CNS Oral Drugs Sales in Value Forecast by Region (2024-2034) & (US$ Million)
Table 32. Americas CNS Oral Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. Americas CNS Oral Drugs Sales in Value by Country (2018-2023) & (US$ Million)
Table 34. Americas CNS Oral Drugs Sales in Value by Country (2024-2034) & (US$ Million)
Table 35. Americas CNS Oral Drugs Sales in Volume by Country (2018-2023) & (K Units)
Table 36. Americas CNS Oral Drugs Sales in Volume by Country (2024-2034) & (K Units)
Table 37. EMEA CNS Oral Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. EMEA CNS Oral Drugs Sales in Value by Country (2018-2023) & (US$ Million)
Table 39. EMEA CNS Oral Drugs Sales in Value by Country (2024-2034) & (US$ Million)
Table 40. EMEA CNS Oral Drugs Sales in Volume by Country (2018-2023) & (K Units)
Table 41. EMEA CNS Oral Drugs Sales in Volume by Country (2024-2034) & (K Units)
Table 42. APAC CNS Oral Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. APAC CNS Oral Drugs Sales in Value by Country (2018-2023) & (US$ Million)
Table 44. APAC CNS Oral Drugs Sales in Value by Country (2024-2034) & (US$ Million)
Table 45. APAC CNS Oral Drugs Sales in Volume by Country (2018-2023) & (K Units)
Table 46. APAC CNS Oral Drugs Sales in Volume by Country (2024-2034) & (K Units)
Table 47. Pfizer Company Information
Table 48. Pfizer Description and Business Overview
Table 49. Pfizer CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 50. Pfizer CNS Oral Drugs Product
Table 51. Pfizer Recent Development
Table 52. Biogen Company Information
Table 53. Biogen Description and Business Overview
Table 54. Biogen CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 55. Biogen CNS Oral Drugs Product
Table 56. Biogen Recent Development
Table 57. Otsuka Company Information
Table 58. Otsuka Description and Business Overview
Table 59. Otsuka CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 60. Otsuka CNS Oral Drugs Product
Table 61. Otsuka Recent Development
Table 62. Novartis Company Information
Table 63. Novartis Description and Business Overview
Table 64. Novartis CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 65. Novartis CNS Oral Drugs Product
Table 66. Novartis Recent Development
Table 67. Teva Pharmaceutical Company Information
Table 68. Teva Pharmaceutical Description and Business Overview
Table 69. Teva Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 70. Teva Pharmaceutical CNS Oral Drugs Product
Table 71. Teva Pharmaceutical Recent Development
Table 72. Johnson & Johnson Company Information
Table 73. Johnson & Johnson Description and Business Overview
Table 74. Johnson & Johnson CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 75. Johnson & Johnson CNS Oral Drugs Product
Table 76. Johnson & Johnson Recent Development
Table 77. AstraZeneca Company Information
Table 78. AstraZeneca Description and Business Overview
Table 79. AstraZeneca CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 80. AstraZeneca CNS Oral Drugs Product
Table 81. AstraZeneca Recent Development
Table 82. Merck Company Information
Table 83. Merck Description and Business Overview
Table 84. Merck CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Merck CNS Oral Drugs Product
Table 86. Merck Recent Development
Table 87. GSK Company Information
Table 88. GSK Description and Business Overview
Table 89. GSK CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. GSK CNS Oral Drugs Product
Table 91. GSK Recent Development
Table 92. Eli Lilly and Company Company Information
Table 93. Eli Lilly and Company Description and Business Overview
Table 94. Eli Lilly and Company CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. Eli Lilly and Company CNS Oral Drugs Product
Table 96. Eli Lilly and Company Recent Development
Table 97. Lundbeck Company Information
Table 98. Lundbeck Description and Business Overview
Table 99. Lundbeck CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. Lundbeck CNS Oral Drugs Product
Table 101. Lundbeck Recent Development
Table 102. Takeda Company Information
Table 103. Takeda Description and Business Overview
Table 104. Takeda CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. Takeda CNS Oral Drugs Product
Table 106. Takeda Recent Development
Table 107. Bristol Myers Squibb Company Information
Table 108. Bristol Myers Squibb Description and Business Overview
Table 109. Bristol Myers Squibb CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Bristol Myers Squibb CNS Oral Drugs Product
Table 111. Bristol Myers Squibb Recent Development
Table 112. Jiangsu Nhwa Pharmaceutical Company Information
Table 113. Jiangsu Nhwa Pharmaceutical Description and Business Overview
Table 114. Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Product
Table 116. Jiangsu Nhwa Pharmaceutical Recent Development
Table 117. Luye Pharma Company Information
Table 118. Luye Pharma Description and Business Overview
Table 119. Luye Pharma CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Luye Pharma CNS Oral Drugs Product
Table 121. Luye Pharma Recent Development
Table 122. Zhejiang Huahai Pharmaceutical Company Information
Table 123. Zhejiang Huahai Pharmaceutical Description and Business Overview
Table 124. Zhejiang Huahai Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. Zhejiang Huahai Pharmaceutical CNS Oral Drugs Product
Table 126. Zhejiang Huahai Pharmaceutical Recent Development
Table 127. Chengdu Easton Biopharmaceuticals Company Information
Table 128. Chengdu Easton Biopharmaceuticals Description and Business Overview
Table 129. Chengdu Easton Biopharmaceuticals CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 130. Chengdu Easton Biopharmaceuticals CNS Oral Drugs Product
Table 131. Chengdu Easton Biopharmaceuticals Recent Development
Table 132. Hansoh Pharmaceutical Company Information
Table 133. Hansoh Pharmaceutical Description and Business Overview
Table 134. Hansoh Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 135. Hansoh Pharmaceutical CNS Oral Drugs Product
Table 136. Hansoh Pharmaceutical Recent Development
Table 137. Key Raw Materials Lists
Table 138. Raw Materials Key Suppliers Lists
Table 139. CNS Oral Drugs Customers List
Table 140. CNS Oral Drugs Distributors List
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. CNS Oral Drugs Product Picture
Figure 2. Global CNS Oral Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global CNS Oral Drugs Market Size 2018-2034 (US$ Million)
Figure 4. Global CNS Oral Drugs Sales 2018-2034 (K Units)
Figure 5. United States CNS Oral Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 6. United States CNS Oral Drugs Market Size 2018-2034 (US$ Million)
Figure 7. United States CNS Oral Drugs Sales 2018-2034 (K Units)
Figure 8. United States CNS Oral Drugs Market Share in Global, in Value (US$ Million) 2018-2034
Figure 9. United States CNS Oral Drugs Market Share in Global, in Volume (K Units) 2018-2034
Figure 10. CNS Oral Drugs Report Years Considered
Figure 11. Product Picture of Antidepressants
Figure 12. Product Picture of Antipsychotics
Figure 13. Product Picture of Anti-Dementia Drugs
Figure 14. Product Picture of Anti-Parkinson's Drugs
Figure 15. Product Picture of Antiepileptic Drugs
Figure 16. Product Picture of Others
Figure 17. Global CNS Oral Drugs Market Share by Type in 2024 & 2034
Figure 18. Global CNS Oral Drugs Sales in Value by Type (2018-2034) & (US$ Million)
Figure 19. Global CNS Oral Drugs Sales Market Share in Value by Type (2018-2034)
Figure 20. Global CNS Oral Drugs Sales by Type (2018-2034) & (K Units)
Figure 21. Global CNS Oral Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 22. Global CNS Oral Drugs Price by Type (2018-2034) & (US$/Unit)
Figure 23. United States CNS Oral Drugs Market Share by Type in 2024 & 2034
Figure 24. United States CNS Oral Drugs Sales in Value by Type (2018-2034) & (US$ Million)
Figure 25. United States CNS Oral Drugs Sales Market Share in Value by Type (2018-2034)
Figure 26. United States CNS Oral Drugs Sales by Type (2018-2034) & (K Units)
Figure 27. United States CNS Oral Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 28. United States CNS Oral Drugs Price by Type (2018-2034) & (US$/Unit)
Figure 29. Product Picture of Hospital and Clinic
Figure 30. Product Picture of Pharmacy
Figure 31. Global CNS Oral Drugs Market Share by Application in 2024 & 2034
Figure 32. Global CNS Oral Drugs Sales in Value by Application (2018-2034) & (US$ Million)
Figure 33. Global CNS Oral Drugs Sales Market Share in Value by Application (2018-2034)
Figure 34. Global CNS Oral Drugs Sales by Application (2018-2034) & (K Units)
Figure 35. Global CNS Oral Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 36. Global CNS Oral Drugs Price by Application (2018-2034) & (US$/Unit)
Figure 37. United States CNS Oral Drugs Market Share by Application in 2024 & 2034
Figure 38. United States CNS Oral Drugs Sales in Value by Application (2018-2034) & (US$ Million)
Figure 39. United States CNS Oral Drugs Sales Market Share in Value by Application (2018-2034)
Figure 40. United States CNS Oral Drugs Sales by Application (2018-2034) & (K Units)
Figure 41. United States CNS Oral Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 42. United States CNS Oral Drugs Price by Application (2018-2034) & (US$/Unit)
Figure 43. Americas CNS Oral Drugs Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 44. Americas CNS Oral Drugs Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 45. Americas CNS Oral Drugs Sales by Type (2018-2034) & (K Units)
Figure 46. Americas CNS Oral Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 47. Americas CNS Oral Drugs Sales by Application (2018-2034) & (K Units)
Figure 48. Americas CNS Oral Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 49. United States CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 50. Canada CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 51. Mexico CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 52. Brazil CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 53. EMEA CNS Oral Drugs Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 54. EMEA CNS Oral Drugs Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 55. EMEA CNS Oral Drugs Sales by Type (2018-2034) & (K Units)
Figure 56. EMEA CNS Oral Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 57. EMEA CNS Oral Drugs Sales by Application (2018-2034) & (K Units)
Figure 58. EMEA CNS Oral Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 59. Europe CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 60. Middle East CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 61. Africa CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 62. China CNS Oral Drugs Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 63. China CNS Oral Drugs Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 64. China CNS Oral Drugs Sales by Type (2018-2034) & (K Units)
Figure 65. China CNS Oral Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 66. China CNS Oral Drugs Sales by Application (2018-2034) & (K Units)
Figure 67. China CNS Oral Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 68. APAC CNS Oral Drugs Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 69. APAC CNS Oral Drugs Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 70. APAC CNS Oral Drugs Sales by Type (2018-2034) & (K Units)
Figure 71. APAC CNS Oral Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 72. APAC CNS Oral Drugs Sales by Application (2018-2034) & (K Units)
Figure 73. APAC CNS Oral Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 74. Japan CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 75. South Korea CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 76. China Taiwan CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 77. Southeast Asia CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 78. India CNS Oral Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 79. CNS Oral Drugs Value Chain
Figure 80. CNS Oral Drugs Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed